Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 19/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 18/20 | 0.67 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.52 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3496263 | 0.90 | KEAP1 (0.58) | NFE2L2KEAP1NSD2NSD1NSD3 | |
| SCHEMBL3491956 | 0.84 | KEAP1 (0.86) | NFE2L2KEAP1 | |
| SCHEMBL18733485 | 0.84 | NFE2L2 (0.73) | NFE2L2KEAP1 | |
| SCHEMBL18706644 | 0.81 | NFE2L2 (0.71) | NFE2L2KEAP1 | |
| SCHEMBL3493057 | 0.79 | NFE2L2 (0.58) | NFE2L2KEAP1 | |
| SCHEMBL3494108 | 0.79 | KEAP1 (0.64) | NFE2L2KEAP1 | |
| SCHEMBL6313505 | 0.78 | RAB9A (0.67) | NFE2L2KEAP1 | |
| SCHEMBL18707350 | 0.78 | NFE2L2 (0.59) | NFE2L2KEAP1 | |
| SCHEMBL3493020 | 0.78 | HCRTR1 (0.47) | NFE2L2KEAP1 | |
| SCHEMBL18733521 | 0.78 | NFE2L2 (0.57) | NFE2L2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | NFE2L2 1103/4885KEAP1 488/4885NSD2 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.